MaxCyte Investor Presentation Deck
MaxCyte Enables Next-Generation Cell Therapies Across a
Variety of Diseases
Indications in Active MaxCyte-Enabled Clinical Trials
Clinical trial = FDA IND clearance or equivalent
Genetic Diseases
Beta-Thalassemia
Sickle Cell Disease
Chronic Granulomatous Disease (CGD)
Hematological Malignancies
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Multiple Myeloma
Non-Hodgkin Lymphoma
T-Cell Lymphoma
Infectious Disease
As of March 2023 / Includes Commercial and Academic Clinical Trials. Source: clinicaltrials.gov
HIV
Solid Tumors
Non-small Cell Lung Cancer
Glioblastoma
Renal Cell Carcinoma
Other Solid Tumors
1,000+
Estimated patients in active clinical trials enabled by MaxCyte
17
M MaxCyte
Gene-Editing Tools used in
MaxCyte-Enabled Clinical Trials
✓ ARCUS
✓ Base-editing (CRISPR)
✓ CRISPR
✓ RNA-Based Engineering
✓ TALENS
✓ Zinc Finger Nucleases (ZFNs)
First MaxCyte-Enabled Therapy is
expected to be approved as early as
2023/2024
Source: Evaluate Pharma
© 2023 MaxCyte, Inc. All Rights ReservedView entire presentation